Leptin as a potential prognostic marker of the severity of COVID-19 infection in obese patients

Maria J. Baltodano-Calle, Jhoanna S. Polo-Vasquez, Alina Romani-Pozo, Diego Gutarra, Emilio Guija-Poma

PII: S0939-4753(21)00562-7
DOI: https://doi.org/10.1016/j.numecd.2021.12.003
Reference: NUMECD 2883

To appear in: Nutrition, Metabolism and Cardiovascular Diseases

Received Date: 3 November 2021
Revised Date: 29 November 2021
Accepted Date: 1 December 2021

Please cite this article as: Baltodano-Calle MJ, Polo-Vasquez JS, Romani-Pozo A, Gutarra D, Guija-Poma E, Leptin as a potential prognostic marker of the severity of COVID-19 infection in obese patients, Nutrition, Metabolism and Cardiovascular Diseases, https://doi.org/10.1016/j.numecd.2021.12.003.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
Author names and affiliations:

[**Maria J. Baltodano-Calle**]
- Universidad Peruana Cayetano Heredia Facultad de Medicina. Lima, Perú.
- Sociedad Científica de Estudiantes De Medicina Cayetano Heredia (SOCEMCH), Lima, Perú

[Jhoanna S. Polo-Vasquez]
- Universidad Peruana Cayetano Heredia Facultad de Medicina. Lima, Perú.
- Sociedad Científica de Estudiantes De Medicina Cayetano Heredia (SOCEMCH), Lima, Perú

[Alina Romani-Pozo]
- Universidad Peruana Cayetano Heredia Facultad de Medicina. Lima, Perú.

[**Diego Gutarra**]
- Universidad Peruana Cayetano Heredia Facultad de Medicina. Lima, Perú.

[**Emilio Guija-Poma**]
- Universidad de San Martín de Porres Facultad de Medicina Humana, Centro de Investigación de Bioquímica y Nutrición. Lima, Perú.
Leptin as a potential prognostic marker of the severity of COVID-19 infection in obese patients

Dear editor,

We read with great interest the article “Obesity as a risk factor for unfavorable outcomes in critically ill patients affected by Covid-19” [1], and we believe this is an important contribution towards understanding the relationship between the severity of the disease COVID-19 and obesity. While we agree on the apparent role of adipokines, we believe that there is evidence suggesting that leptin may have a significant role in the underlying mechanisms of severe COVID-19 in obese patients due to its important immunological function. [1]

Since the onset of the COVID-19 pandemic, obesity has been associated with poorer outcomes of COVID-19 infections. A study by Biscarini et al. identified this association in the earlier times of the pandemic (February-March 2020) by analyzing the data from 427 COVID-19 patients referred to a hospital in Italy and the results showed that 33% of obese patients required admission to ICU compared to 19% of non-obese patients [2]. Later on, Bellini et al. analyzed a large population registered in the Tuscany regional database and concluded that there was an association between obesity and the risk of hospitalization (RR 1.74, 95% CI: [1.56–1.97]) [3]. Furthermore, Zeng et al. retrospective study of the Wuhan's inpatients' data, revealed that an increased BMI positively correlated with the severity of many symptoms such as fever, dyspnea, and ground-glass opacity CT scan (p<0.05) with a hazard ratio (HR) of 2.54 for mortality with COVID-19 in obese patients [4]. Thus, the association between obesity and unfavorable outcomes for COVID-19 patients appears to be robust across geography and it stands even after adjusting the confounding variables such as age, sex, and comorbidities.

Multiple other studies have further supported the association between obesity and severity of COVID-19 infection but some studies suggest the role of adipokines in this mechanism. Cai et al. published a meta-analysis including 46 articles where obesity was associated with a high risk of mortality (OR 1.61, 95% CI: [1.29–2.01]), hospitalization (OR 1.72, 95% CI: [1.55–1.92]), and clinically severe disease (OR 3.81, 95% CI: [1.97–7.35]) and suggested that adipokines may have a role in this association as the imbalance caused by the inflammatory status observed in obese individuals may dysregulate the immune response resulting in increased susceptibility to viral infections like COVID-19 [5]. Particularly, leptin's pro-inflammatory functions, such as activation of M1 monocytes, may play an important role in the cytokine storm related to COVID-19 aggravation, acute respiratory distress syndrome, and multiple organ failure; especially in obese patients, whose fat mass excess produce more leptin upon infection [6].

Hyperleptinemia is one of the clinical characteristics associated with SARS-CoV-2 ventilated patients admitted to ICU [7]. Van de Voort et al. found that SARS-CoV-2 ventilated patients had higher levels of serum leptin (p = 0.0007) [7]. Similarly, Wang et al. reported increased leptin levels, in patients with BMI > 24, in both mild and severe COVID-19 patients with the later group exhibiting significantly higher levels [8]. Notably, leptin levels are associated with the immunologic abnormalities and systemic pro-inflammatory state seen in COVID-19 patients [8]. Also, the finding of an increase in visceral fat in severe patients compared to mild ones could suggest that the use of leptin as a biomarker of inflammation could be useful to
determine the risk of COVID-19 and its possible complications even in patients with central obesity. [9].

All of these studies support the association of leptin and severe COVID-19 in obese patients. However, many of them have limitations such as limited medical resources and sample sizes. Therefore, more research should be conducted to further understand leptin's role in severe COVID-19 patients and maybe, in the future, use leptin as a therapeutic target. Also, it is important to evaluate its potential as a prognostic marker to anticipate complications of its release in obese patients. Finally, we emphasize the importance of leptin as a molecule with diverse immunological functions that can not only help address COVID-19 disease's progression but also in ensuring the development of effective vaccines for obese patients whose elevated serum leptin levels could downregulate antibody production and class switching [10].

**Competing interests:**
The authors declare no conflicts of interest.

**References:**


